Sarah Bennett
Yellow fever is a dangerous viral infection transmitted by mosquitoes that can cause severe illnesses, including high fever, headaches, jaundice, bleeding, organ failure, and even death. While the yellow fever vaccine is generally considered safe and effective, offering long-lasting protection with a single dose, there are specific concerns regarding its administration to individuals aged 60 and above. This is primarily due to the increased risk of adverse reactions in this age group, with studies indicating a higher likelihood of serious side effects, including neurological and viscerotropic diseases. Therefore, for individuals over 60, a comprehensive risk assessment is recommended to determine whether the benefits of vaccination outweigh the potential risks.
| Characteristics | Values |
|---|---|
| Risk of serious adverse events | 3 times higher for the elderly compared to the non-elderly population |
| Risk of viscerotropic disease | 6 times higher compared to the population < 60 years |
| Risk of adverse events for > 70 years | 5 times higher |
| Risk of neurological disease (YEL-AND) | 2.2 cases per 100,000 doses |
| Risk of viscerotropic disease (YEL-AVD) | 1.2 cases per 100,000 doses |
| Risk of life-threatening side effects | Higher for people over 60 |
| Risk of other health complications | Higher due to weakened immune system |
Explore related products
![International Certificate of Vaccination with Vinyl Document Holder - World Health Organization Bilingual Version [cards] World Health Organization [Jan 01, 2007]](https://m.media-amazon.com/images/I/61SHjBP1VYL._AC_UY218_.jpg)
What You'll Learn
Higher risk of life-threatening side effects
Yellow fever is a dangerous viral infection transmitted to people by certain types of mosquitoes. It can cause serious illnesses such as headache, muscle soreness, jaundice, bleeding, and sometimes even death. There is no cure or effective treatment for yellow fever, making vaccination the best way to protect oneself before travelling to areas where the disease is prevalent.
The yellow fever vaccine is considered safe and effective, requiring only one dose to ensure protection against the disease. However, in rare cases, people may develop severe, sometimes life-threatening reactions to the vaccine. These reactions include allergic reactions with difficulty breathing or swallowing (anaphylaxis), swelling of the brain, spinal cord, or surrounding tissues (encephalitis or meningitis), and Guillain-Barré syndrome, a nervous system disorder that can cause muscle weakness and paralysis.
For individuals aged 60 and above, there are specific concerns regarding the side effects of the yellow fever vaccine. With advancing age, the immune system may weaken, increasing the likelihood of serious side effects, although such cases are rare. The risk of adverse events is estimated to be 2.51 times higher for individuals aged 60 and older compared to those under 60. This risk increases further for individuals over 70, who are at a five times higher risk compared to those under 60.
When considering vaccination for travellers aged 60 and above, a comprehensive risk assessment is necessary. This includes evaluating the individual's health history and the specific requirements of their travel destination. For those with other health conditions, the potential risks of the vaccine may outweigh the benefits. In such cases, alternative options such as obtaining a medical exemption certificate or changing the travel itinerary to avoid high-risk areas may be more prudent.
Puppy Vaccines: 5-in-1 Protection
You may want to see also
Explore related products
Increased risk of adverse events following immunisation (AEFI)
The yellow fever vaccine is a live, weakened form of the virus, and a single dose is typically enough to confer lifelong protection against the disease. However, the vaccine is not without risks, and certain groups, such as those over 60, may face an increased risk of adverse events following immunisation (AEFI).
Yellow fever vaccine-associated neurological disease (YEL-AND) is a rare but serious complication that affects the brain and nervous system, causing symptoms such as confusion and problems with movement and coordination. The risk of YEL-AND is estimated at 2.2 cases per 100,000 doses of the vaccine. Another rare but severe complication is yellow fever vaccine-associated viscerotropic disease (YEL-AVD), which mimics the effects of yellow fever itself, including multi-organ failure and death in approximately 48% of cases. The risk of YEL-AVD is estimated at 1.2 cases per 100,000 doses.
The risk of experiencing serious adverse events after yellow fever vaccination is significantly higher in individuals over 60 years of age. A meta-analysis of multiple studies found that the risk of serious adverse events was 2.51 times higher in this age group when compared to those under 60. The analysis also revealed that the risk increased to three times higher for individuals over 70 and was even higher for those over 60 with comorbidities. This increased risk is attributed to the natural process of immunosenescence, where the immune system weakens with age, making older adults more susceptible to adverse events.
Due to the higher risk of life-threatening side effects, the yellow fever vaccine is generally not recommended for individuals aged 60 and above unless there is a significant and unavoidable risk of acquiring yellow fever. In such cases, a comprehensive risk assessment should be undertaken to weigh the benefits of vaccination against the potential risks. For those who cannot be vaccinated, alternative options, such as obtaining a medical exemption or waiver, may be considered.
Combination Skin: What's True and False?
You may want to see also
Explore related products
Higher risk of vaccine-associated viscerotropic disease (YEL-AVD)
The yellow fever vaccine is not recommended for people over 60 due to the risk of vaccine-associated viscerotropic disease (YEL-AVD). This is a serious condition that can cause multi-organ failure and death. The risk of YEL-AVD is estimated to be 1.2 cases per 100,000 doses of the vaccine.
YEL-AVD is very similar to yellow fever itself and can be life-threatening. It is characterized by multi-organ failure and death in approximately 48% of cases. Due to the severity of this condition, the vaccine is generally not recommended for people over 60 unless there is a significant and unavoidable risk of acquiring yellow fever infection, such as travel to an area with ongoing outbreaks or periodic risk of yellow fever transmission.
The risk of YEL-AVD is higher in people over 60 due to the natural process of immunosenescence, which weakens the immune system with age. As a result, older adults are more susceptible to infectious diseases and may experience more severe symptoms and complications if infected. This increased vulnerability, combined with the potentially severe side effects of the vaccine, contributes to the higher risk of YEL-AVD in this age group.
Additionally, it is important to note that almost all cases of YEL-AVD have occurred in first-time vaccine recipients. This information is crucial when considering the vaccination of individuals aged 60 and older. A comprehensive risk assessment is necessary to weigh the benefits and potential dangers of the vaccine for this age group.
While the yellow fever vaccine is generally considered safe and effective for most people, the risk of serious adverse events, including YEL-AVD, is significantly higher in the elderly population. Therefore, it is recommended that individuals over 60 who are considering travel to yellow fever-endemic areas seek professional medical advice and undergo a thorough individual benefit-risk assessment before making an informed decision about vaccination.
Writing Religious Exemption for Vaccines in Pennsylvania
You may want to see also
Explore related products
Higher risk of vaccine-associated neurologic disease (YEL-AND)
Yellow Fever Vaccine-associated Neurological Disease (YEL-AND) is a rare but serious condition that affects the brain and nervous system. It can cause symptoms such as confusion, movement problems, and coordination issues. The risk of YEL-AND is estimated at approximately 2.2 cases per 100,000 doses of the vaccine. While this may seem like a low probability, the consequences can be severe and life-threatening.
YEL-AND is a higher risk for individuals over 60 years of age due to the natural weakening of the immune system that occurs with ageing, known as immunosenescence. As a result of this natural process, older adults are more susceptible to adverse events from the vaccine. The risk of serious adverse events after yellow fever vaccination is estimated to be three times higher for individuals over 60 when compared to the non-elderly population, and it increases to five times higher for those over 70.
The decision to vaccinate individuals over 60 must be carefully considered, taking into account the specific circumstances and health status of the individual. A comprehensive risk assessment is necessary, including an evaluation of the person's medical history and the risk of acquiring yellow fever infection during travel. For those over 60, the vaccine is generally recommended only when there is a significant and unavoidable risk of yellow fever exposure, such as travel to endemic areas.
In some cases, alternative options may be considered to avoid the potential risks associated with the yellow fever vaccine for older adults. This could include changing travel plans to avoid high-risk areas or obtaining a medical exemption certificate, which some countries may accept as an alternative to vaccination. Seeking professional advice and information about the risks and benefits of the vaccine is crucial for individuals over 60 considering yellow fever vaccination.
Vaccine Spacing and Timing: Why It Matters
You may want to see also
Explore related products
Risk of serious adverse events three times higher for the elderly
The yellow fever vaccine is a live, weakened form of the virus that usually requires only one dose to ensure protection against the disease. For most people, the adverse effects of the vaccine are mild and may include headaches, muscle aches, and low-grade fevers. However, in rare cases, individuals may develop severe, sometimes life-threatening reactions to the vaccine.
The risk of serious adverse events after the yellow fever vaccination is three times higher for individuals aged 60 and above when compared to the non-elderly population. This risk increases to five times for those over 70. As a result of this increased risk, the yellow fever vaccine is generally not recommended for individuals in this age group unless they are travelling to areas with a current or periodic risk of yellow fever transmission.
The higher risk of adverse events in the elderly is attributed to the natural process of immunosenescence, which weakens the immune system with age. Additionally, elderly individuals with comorbidities are more susceptible to contracting infectious diseases and experiencing exacerbations of clinical symptoms, which can lead to complications and death.
To mitigate the risks associated with the yellow fever vaccine in the elderly, a comprehensive risk assessment is necessary. This includes considering the individual's health history, the prevalence of yellow fever at their travel destination, and the availability of alternative preventative measures or medical exemptions. Seeking professional advice and information about the risks and benefits of the vaccine is crucial for making an informed decision.
Hep B Vaccine: Who Pays When Employers Require It?
You may want to see also
Frequently asked questions
The yellow fever vaccine is not recommended for people over 60 due to the risk of serious side effects, which become more likely with age.
Side effects of the Yellow Fever vaccine are generally mild and include headaches, muscle aches, and low-grade fevers. However, in rare cases, people may develop severe, sometimes life-threatening reactions such as anaphylaxis, encephalitis, meningitis, or Guillain-Barré syndrome.
Yellow Fever is a serious illness spread by mosquitoes that can cause high fever, headaches, jaundice, bleeding, and, in severe cases, organ failure or death. The virus is found in parts of Africa, South America, Central America, and the Caribbean.
If you are over 60 and planning to travel to an area where Yellow Fever is present, it is important to assess the risks carefully. Speak to a healthcare professional about your travel plans and health history to determine whether the vaccine is recommended for you, or whether a medical exemption or waiver may be more appropriate.
